TriangleNCT00445068 · REGISTRY CONDITION SEARCH
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- TERMINATED
- Registry last update
- 2021-07-14
This study will evaluate the efficacy and safety of LBH589B in adult patients with multiple myeloma who have received at least two prior therapies and are refractory to their last therapy. Patients must have received in prior therapy either bortezomib or lenalidomide
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Response Rate (Complete Response(CR) / Partial Response (PR))
Overall Response Rate
Clinical Benefit Rate
Duration of Response
Time to Response
Progression Free Survival (PFS)
Safety and Tolerability
Time to Peak Concentration (Tmax) of Panobinostat
Maximum Plasma Concentration (Cmax) of Panobinostat
Area Under the Plasma Concentration (AUC0-24) of Panobinostat
Last Observed Plasma Concentration (Clast) of Panobinostat
Time of Clast (Tlast) of Panobinostat
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion criteria: 1. Adults ≥ 18 years old 2. Subjects must have signed the consent form before undergoing any study specific screening procedures and before participation in this study. The subject must be fully informed by the investigator of the nature and potential risks of participation in this study. 3. Patients must have had a diagnosis of symptomatic multiple myeloma (from IMWG see (Kyle et al,2003) meeting all three of the following criteria: * Monoclonal immunoglobulin (spike on electrophoresis, or band on immunofixation) on serum or on 24 hour urine. * Bone marrow (clonal) plasma cells or plasmacytoma * Related organ or tissue impairment (anemia, hypercalcemia, lytic bone lesions, renal insufficiency, hyperviscosity or recurrent infections) (The Kyle et al 2003 definition of symptomatic Myeloma has been adapted based on the new exclusion criteria defined in protocol amendment 1) 4. Subjects must have received at least two prior lines of therapy and be refractory to the most recent line of therapy according to the following definitions: Refractory to most recent line of therapy Defined by disease progression during treatment or within 60 - 100 days after the completion of the most recent line of therapy. This includes the development of disease progression during maintenance or consolidation therapy with high dose glucocorticoids, or any other specific MM therapy Sixty days is counted from the point in time when the first response assessment is performed after completion of the last line of therapy. At a maximum, disease progression should be documented within 100 days after the last day of the last dose of any anti-MM therapy, including if last regimen of the most recent line of therapy was Autologous Stem Cell Transplant (ASCT). Stable disease patients also part of the IMWG definition are not eligible for this trial. At study screening, Progressive Disease (PD) will be assessed by comparing screening values or symptoms in reference to the baseline (values or symptoms) of their last line of therapy. Should a patient have experienced an initial response on their last line of therapy, PD should be assessed in reference to the lowest values of the initial confirmed response Minimal Response(MR) / Partial Response (PR) / Complete Response (CR). Disease progression is defined by having one or more of the following: * \>25% increase in the level of serum monoclonal paraprotein, which must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation. * \>25% increase in 24-hour urinary light chain excretion, which must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation. * \>25% increase in plasma cells in a bone marrow aspirate or on bone marrow biopsy, which must also be an absolute increase of at least 10% * Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas. * Development of new bone lesions or soft tissue plasmacytomas (not including compression fracture). * Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL or 2.8 mmol/L not attributable to any other cause). 5. Subjects must have previously been treated with bortezomib and at least one of the following: lenalidomide or thalidomide 6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2 7. Patients must have the following hematological laboratory values: * Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L (or ≥1.0 x 109/L if the neutropenia is clinically related to progressive myeloma with bone marrow infiltration of \> 50% involvement * Hemoglobin ≥ 8.0 g/dl * Platelets ≥ 75.0 x 109/L (or ≥ 50.0 x 109/L x if the thrombocytopenia is clinically related to progressive myeloma with bone marrow infiltration \> 50% involvement 8. Patients must have the following renal function as shown by : * Calculated Creatinine Clearance (CrCL) \> 30ml/min (Cockcroft and Gault formula) 9. Patients must have adequate liver function as shown by: * Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 x Upper limit of normal (ULN) * Serum bilirubin ≤ 1.5 x ULN * Albumin ≥ 2.5 g/dl 10. Patients must have the following non-hematological laboratory values: * Serum potassium ≥ Lower Limit of Normal (LLN), * Total serum calcium \[corrected for serum albumin\] or ionized calcium ≥LLN, * Serum magnesium ≥ LLN * Serum phosphorus ≥ LLN * Normal thyroid function (TSH and free T4) (hypothyroidism correctable with supplements is allowed) 11. Baseline Multiple Uptake Gated Acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate Left Ventricular Ejection Fraction (LVEF) ≥ the lower limit of the institutional normal 12. Patients must be willing and able to undergo bone marrow aspirates as per protocol, with/without bone marrow biopsy according to their center's practice. The bone marrow aspirate /biopsy must be adequate to allow for comparison for the later efficacy response assessments. 13. Patients must have an M component at baseline above a minimum threshold of: 1g/dl (10g/L) for serum M component, or 200mg/24h urine M component. Exclusion criteria: 1. Prior therapy with an Histone Deacetylase (HDAC) inhibitor for the treatment of Multiple Myeloma (MM) 2. Patients with non-secretory MM 3. Patients who have received allogenic stem cell transplantation \< 12 months prior to study 4. Patients who have had prior allogenic stem cell transplantation and show evidence of active graft versus-host disease that requires immunosuppressive therapy 5. Patients with amyloidosis 6. Patients with peripheral neuropathy \> grade 2 7. Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: * Patients with congenital long QT syndrome * History or presence of sustained ventricular tachyarrhythmia. (Patients with a history of atrial arrhythmia are eligible but should be discussed with the Sponsor prior to enrollment) * Any history of ventricular fibrillation or torsade de pointes * Bradycardia defined as Heart Rate (HR)\< 50 bpm. Patients with pacemakers are eligible if HR ≥ 50 bpm. * Screening Electrocardiogram (ECG) with a corrected QT interval (QTc) \> 450 msec * Right bundle branch block + left anterior hemi-block (bi-fascicular block) * Patients with myocardial infarction or unstable angina ≤ 6 months prior to starting study drug 8. Other clinically significant heart disease (e.g., Congestive Heart Failure (CHF NY) Heart Association class III or IV, uncontrolled hypertension, or history of poor compliance with an antihypertensive regimen) 9. Impairment of GI function or GI disease that may significantly alter the absorption of LBH589 10. Patients with unresolved diarrhea \> CTCAE grade 1. 11. Other concurrent severe and/or uncontrolled medical conditions that could cause unacceptable safety risks or compromise compliance with the protocol 12. Patients using medications that have a relative risk of prolonging the QT interval or inducing torsades de pointes if the medications cannot be discontinued or switched to a different medication prior to starting study drug 13. Concomitant use of CYP3A4 inhibitors 14. Patients with an active bleeding diathesis or on any treatment with therapeutic doses of sodium warfarin (Coumadin®) or any other anti-vitamin K drug. Low doses of Coumadin® (e.g., ≤ 2 mg/day), or low doses of any other anti-vitamin K drug, for line patency is allowable 15. Patients who have received chemotherapy, radiation therapy or any investigational drugs, bortezomib or other immunomodulatory therapy (e.g., thalidomide, lenalidomide) or immunotherapy ≤ 3 weeks prior to starting study drug or who have not recovered from side effects of such therapy 16. Patients who have received high-dose corticosteroids as the only component of their most recent line of therapy 17. Patients who have received steroids (e.g., dexamethasone) ≤ 2 weeks prior to starting study treatment or who have not recovered from side effects of such therapy. Concomitant therapy medications that include corticosteroids are allowed if subjects receive \< 20 mg of prednisone or equivalent as indicated for other medical conditions (and not as maintenance or an anticancer therapy for MM), or up to 100 mg of hydrocortisone as premedication for a administration of certain medications or blood products, while enrolled in this study. 18. Patients whose clinical condition would need valproic acid therapy during study or ≤ 5 days prior to starting drug 19. Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy 20. Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)not willing to use a double method of contraception during the study and for 3 months after treatment. One of these methods of contraception must be a barrier method. WOCBP are defined as women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). Women of childbearing potential must have a negative serum pregnancy test within 7 days of the first administration of oral LBH589 21. Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and for 3 months after treatment. One of these methods of contraception must be a condom 22. Patients with a current second malignancy or a prior malignancy within the last 5 years except adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer 23. Patients with any significant history of non compliance to medical regimens or unwilling or unable to comply with the protocol or unable to grant reliable informed consent.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants received panobinostat 20 milligrams (mg) orally once daily (OD), three times a week on days: 1, 3 and 5, then 8, 10 and 12, then 15, 17 and 19 of each cycle, as part of a 3-week (21 days) treatment cycle. Participants could continue treatment until disease progression or unacceptable toxicity.
- intervention Names
- Drug: LBH589
- label
- Panobinostat
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Panobinostat
- name
- LBH589
- other Names
- Panobinostat
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 38
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- The response (complete response (CR) / partial response (PR)) rate as per Bladé criteria was assessed by the investigator. Response to treatment was evaluated in participants with multiple myeloma (MM) who have received at least two prior lines of therapy and whose disease was refractory to the most recent line of therapy.
- measure
- Response Rate (Complete Response(CR) / Partial Response (PR))
- time Frame
- From Start of the Study up to 57 Weeks approximately.
- secondary Outcomes
- description
- Overall response rate is the proportion of patients with a best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria (Overall Response (OR) = CR + PR). Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
- measure
- Overall Response Rate
- time Frame
- From Start of the Study up to 57 Weeks approximately.
- description
- Clinical benefit rate is defined by the percentage of participants achieving either a confirmed tumor response or stable disease (SD) for at least 24 weeks. Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A "partial response" requires a decrease of 30% or more, "Progression" requires an increase of at least 20%, and "Stable disease" falls in between these two. All responses have a repeat assessment to confirm the response
- measure
- Clinical Benefit Rate
- time Frame
- From Start of the Study up to 57 Weeks approximately.
- description
- Duration of response is defined as time between time to first documented response (CR/PR) and time to first documented disease progression or death.
- measure
- Duration of Response
- time Frame
- From Start of the Study up to 57 Weeks approximately.
- description
- Time to response is defined as time between Day 1 cycle 1 and time to first documented response (CR/PR).
- measure
- Time to Response
- time Frame
- From Start of the Study up to 57 Weeks approximately.
- description
- Progressions free survival is defined as time between Day 1 cycle 1 and time to first documented disease progression or death. Disease progression will be determined as per response criteria.
- measure
- Progression Free Survival (PFS)
- time Frame
- From Start of the Study up to 57 Weeks approximately.
- description
- Adverse Event (AE) are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.
- measure
- Safety and Tolerability
- time Frame
- From Start of the Study up to 57 Weeks approximately.
- description
- Tmax is defined as the time at which the Cmax occurs. It will be obtained from the Tmax parameter calculated by WinNonlin®. If there is no measurable Cmax in the subject's pharmacokinetic (PK) profile, then Tmax will be missing for that subject. Tmax will be reported in units of h.
- measure
- Time to Peak Concentration (Tmax) of Panobinostat
- time Frame
- Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8
- description
- Cmax is defined as the maximum observed drug concentration observed in plasma over all PK sample concentrations. It will be obtained from the Cmax parameter calculated by WinNonlin®. If there is no measurable concentration in the subject's PK profile, then Cmax will be missing for that subject. Cmax will be reported in units of ng/mL.
- measure
- Maximum Plasma Concentration (Cmax) of Panobinostat
- time Frame
- Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8
- description
- Area under the curve (AUC) is defined as the area under concentration-time curve as a measure of drug exposure. The area under the plasma concentration-time curve from time zero to 24 hours.
- measure
- Area Under the Plasma Concentration (AUC0-24) of Panobinostat
- time Frame
- Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8
- description
- Clast is defined as the Last observed (quantifiable) plasma concentration (Clast), in units of ng/mL. Blood samples were collected to assess Clast.
- measure
- Last Observed Plasma Concentration (Clast) of Panobinostat
- time Frame
- Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8
- description
- Time of Clast (Tlast) will be obtained from the Tlast parameter calculated by WinNonlin®. If there is no measurable concentration in the subject's PK profile, then Tlast will be missing for that participants. Tlast will be reported in units of h.
- measure
- Time of Clast (Tlast) of Panobinostat
- time Frame
- Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8
Full study description
- brief Summary
- This study will evaluate the efficacy and safety of LBH589B in adult patients with multiple myeloma who have received at least two prior therapies and are refractory to their last therapy. Patients must have received in prior therapy either bortezomib or lenalidomide
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-dd9d20d3595dd45a1c0d
- requested nct id
- NCT00445068
- primary nct id
- NCT00445068
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- payload sha256
- 0c552875d40d6f8a1cbc4602df9417ee49f7ce76daef4775ea2d6c182adf61f5
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-dd9d20d3595dd45a1c0d
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT00445068
- occurrences
- context exact
- NCT00445068
- end
- 11
- exact text
- NCT00445068
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Plasma Cell Neoplasms
- query disease state id
- ds-plasma-cell-neoplasms
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- source json pointer
- /studies/791/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- aac5f189b4db321711c9370f482e559d4d587966c3135362321113171b7c7be6
Preserved source evidence · Not medical advice